Menopause & hormone replacement therapy
menopause/HRT · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Permanent cessation of ovarian function with oestrogen deficiency causing vasomotor, urogenital and bone effects. Individualised hormone replacement relieves symptoms and protects bone when benefits outweigh risks.
Red flags
- Unexpected postmenopausal or unscheduled bleeding (exclude endometrial cancer)
- New breast lump
- Symptoms/signs of venous thromboembolism
- New focal neurology/severe headache
- Premature menopause <40 (needs replacement until average menopausal age)
Assessment
Differential diagnosis
- Thyroid dysfunction
- Primary ovarian insufficiency (if <40)
- Anxiety/depression
- Phaeochromocytoma/carcinoid (flushing)
- Medication side effects
Investigations
- Usually clinical in women >45 with typical symptoms (no hormone testing needed)
- FSH if <45 or diagnosis uncertain (two raised levels)
- TSH to exclude thyroid disease
- Bone density if fracture risk concerns
- Lipids/cardiovascular risk assessment before therapy
Management
- Diagnose clinically in women over 45 with characteristic symptoms
- Assess symptom burden, contraindications and personal/family history (breast cancer, VTE)
- Discuss benefits (symptoms, bone, possibly cardiovascular if started early) and risks
- Choose oestrogen route: transdermal preferred for VTE/migraine/higher risk
- Add progestogen for endometrial protection in women with a uterus (cyclical or continuous)
- Offer vaginal oestrogen for isolated urogenital symptoms regardless of systemic therapy
- Use non-hormonal options (SSRIs/SNRIs, CBT, fezolinetant) where HRT is unsuitable
- Review at 3 months then annually, reassessing need and dose
- Provide contraception advice (HRT is not contraceptive) and bone/lifestyle measures
Drugs & doses
Transdermal estradiol patch 25-100 micrograms twice weekly or gel daily
Micronised progesterone 100-200 mg PO nocte (or levonorgestrel IUS) for endometrial protection
Vaginal estriol/estradiol for urogenital atrophy
Fezolinetant 45 mg PO once daily (non-hormonal NK3 antagonist for vasomotor symptoms)
Disposition
Manage in primary care; refer complex cases (breast cancer history, premature menopause, treatment-resistant symptoms) to menopause/endocrine specialists and investigate any abnormal bleeding.
Complications & pitfalls
- Venous thromboembolism (mainly oral oestrogen)
- Small increase in breast cancer risk with combined HRT
- Endometrial hyperplasia if unopposed oestrogen in a woman with a uterus
- Undertreated osteoporosis if HRT withheld inappropriately
Exam pearls
- Transdermal oestrogen avoids the first-pass VTE risk of oral preparations
- Women with a uterus always need a progestogen to protect the endometrium
- Vaginal oestrogen is safe long-term and barely absorbed systemically
- Primary ovarian insufficiency requires replacement to at least the average age of menopause
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.